Literature DB >> 28834746

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.

Maria Gato-Cañas1, Miren Zuazo1, Hugo Arasanz2, Maria Ibañez-Vea1, Laura Lorenzo1, Gonzalo Fernandez-Hinojal2, Ruth Vera3, Cristian Smerdou4, Eva Martisova4, Imanol Arozarena1, Claudia Wellbrock5, Diana Llopiz4, Marta Ruiz4, Pablo Sarobe4, Karine Breckpot6, Grazyna Kochan7, David Escors8.   

Abstract

PDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation through prevention of PDL1-PD1 T cell inhibitory interactions. Here, we find that PDL1 cell-intrinsic signaling protects cancer cells from interferon (IFN) cytotoxicity and accelerates tumor progression. PDL1 inhibited IFN signal transduction through a conserved class of sequence motifs that mediate crosstalk with IFN signaling. Abrogation of PDL1 expression or antibody-mediated PDL1 blockade strongly sensitized cancer cells to IFN cytotoxicity through a STAT3/caspase-7-dependent pathway. Moreover, somatic mutations found in human carcinomas within these PDL1 sequence motifs disrupted motif regulation, resulting in PDL1 molecules with enhanced protective activities from type I and type II IFN cytotoxicity. Overall, our results reveal a mode of action of PDL1 in cancer cells as a first line of defense against IFN cytotoxicity.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B7-H1; CD274; PD-L1; PD1; PDL1; immunotherapy; interferon; signal transduction

Mesh:

Substances:

Year:  2017        PMID: 28834746     DOI: 10.1016/j.celrep.2017.07.075

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  84 in total

1.  Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.

Authors:  Xiaodong Wang; Xiaohui Yang; Chang Zhang; Yang Wang; Tianyou Cheng; Liqiang Duan; Zhou Tong; Shuguang Tan; Hangjie Zhang; Phei Er Saw; Yinmin Gu; Jinhua Wang; Yibi Zhang; Lina Shang; Yajuan Liu; Siyuan Jiang; Bingxue Yan; Rong Li; Yue Yang; Jie Yu; Yunzhao Chen; George Fu Gao; Qinong Ye; Shan Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-11       Impact factor: 11.205

2.  Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.

Authors:  Jon Zugazagoitia; Yuting Liu; Maria Toki; John McGuire; Fahad Shabbir Ahmed; Brian S Henick; Richa Gupta; Scott N Gettinger; Roy S Herbst; Kurt A Schalper; David L Rimm
Journal:  J Thorac Oncol       Date:  2019-10-09       Impact factor: 15.609

3.  The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.

Authors:  Jong Woo Lee; Yu Zhang; Kyung Jin Eoh; Roshan Sharma; Miguel F Sanmamed; Jenny Wu; Justin Choi; Hee Sun Park; Akiko Iwasaki; Edward Kaftan; Lieping Chen; Vali Papadimitrakopoulou; Roy S Herbst; Ja Seok Koo
Journal:  J Thorac Oncol       Date:  2019-02-13       Impact factor: 15.609

Review 4.  Regulation and Function of the PD-L1 Checkpoint.

Authors:  Chong Sun; Riccardo Mezzadra; Ton N Schumacher
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

Review 5.  Checkpoint Molecules in Rheumatology-or the Benefits of Being Exhausted.

Authors:  Stinne Ravn Greisen; Bent Deleuran
Journal:  Curr Rheumatol Rep       Date:  2021-03-02       Impact factor: 4.592

6.  PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.

Authors:  Brian Diskin; Salma Adam; Marcelo F Cassini; Gustavo Sanchez; Miguel Liria; Berk Aykut; Chandan Buttar; Eric Li; Belen Sundberg; Ruben D Salas; Ruonan Chen; Junjie Wang; Mirhee Kim; Mohammad Saad Farooq; Susanna Nguy; Carmine Fedele; Kwan Ho Tang; Ting Chen; Wei Wang; Mautin Hundeyin; Juan A Kochen Rossi; Emma Kurz; Muhammad Israr Ul Haq; Jason Karlen; Emma Kruger; Zennur Sekendiz; Dongling Wu; Sorin A A Shadaloey; Gillian Baptiste; Gregor Werba; Shanmugapriya Selvaraj; Cynthia Loomis; Kwok-Kin Wong; Joshua Leinwand; George Miller
Journal:  Nat Immunol       Date:  2020-03-09       Impact factor: 25.606

7.  Type 1 IFN and PD-L1 Coordinate Lymphatic Endothelial Cell Expansion and Contraction during an Inflammatory Immune Response.

Authors:  Erin D Lucas; Jeffrey M Finlon; Matthew A Burchill; Mary K McCarthy; Thomas E Morrison; Tonya M Colpitts; Beth A Jirón Tamburini
Journal:  J Immunol       Date:  2018-07-25       Impact factor: 5.422

8.  A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.

Authors:  Balamayoora Theivanthiran; Kathy S Evans; Nicholas C DeVito; Michael Plebanek; Michael Sturdivant; Luke P Wachsmuth; April Ks Salama; Yubin Kang; David Hsu; Justin M Balko; Douglas B Johnson; Mark Starr; Andrew B Nixon; Alisha Holtzhausen; Brent A Hanks
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

9.  The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis.

Authors:  Shu Zhao; Minghui Zhang; Yu Zhang; Hongxue Meng; Yan Wang; Yupeng Liu; Jing Jing; Lan Huang; Mengqi Sun; Yue Zhang; Qingyuan Zhang
Journal:  Cancer Biol Med       Date:  2018-08       Impact factor: 4.248

10.  ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.

Authors:  Patrick G Pilié; Chuandong Geng; Zhe Tang; Ganiraju C Manyam; Guang Yang; Sanghee Park; Daoqi Wang; Shan Peng; Cheng Wu; Guang Peng; Timothy A Yap; Paul G Corn; Bradley M Broom; Timothy C Thompson
Journal:  Clin Cancer Res       Date:  2021-06-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.